Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

UK Life Sciences

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

- PMLiVE

UKHSA and The Pirbright Institute collaborate to develop vaccines against henipaviruses

There are currently no licensed vaccines or treatments for the Nipah virus

- PMLiVE

AstraZeneca expands rare disease pipeline with $1.05bn Amolyt Pharma acquisition

The deal gives the company access to a late-stage candidate being evaluated for hypoparathyroidism

- PMLiVE

AstraZeneca announces plans to invest £650m in UK to boost life sciences sector

The investment will also help to enhance public health protection and pandemic preparedness in the UK

- PMLiVE

New nanoparticle to deliver vaccines and generate strong immune responses at lower dose

MOF activates the innate immune system through TLRs to provoke strong immune responses

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu not recommended by NICE for advanced breast cancer

Breast cancer is the most common form of cancer in the UK, accounting for over 55,000 cases every year

- PMLiVE

ICR study reveals AstraZeneca’s ceralasertib sensitises tumours to immunotherapy

Results showed that the drug stopped tumour growth in more than half of patients

- PMLiVE

AstraZeneca’s Voydeya receives CHMP recommendation for rare blood disease PNH

Up to 20% of PNH patients treated with a C5 inhibitor experience clinically significant extravascular haemolysis

- PMLiVE

AstraZeneca’s Tagrisso shows promise as lung cancer maintenance therapy

Up to 85% of lung cancer patients are diagnosed with non-small cell lung cancer

- PMLiVE

ABPI sets out UK life sciences industry’s priorities for government’s budget

The ABPI highlights four key areas where the budget could boost UK life sciences

Can Cinderella save us?

PACE announces partnership with UKHSA to tackle antimicrobial resistance

AMR is designated by WHO as one of the top ten threats to global public health

- PMLiVE

AstraZeneca’s Tagrisso combination approved by FDA for advanced lung cancer

An estimated 200,000 people in the US are diagnosed with lung cancer every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links